非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.02.013

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血清同型半胱氨酸(HCY)、成纤维细胞生长因子21(FGF21)和核因子-κB(NF-κB)水平变化及其临床意义。方法 2020年5月～2022年3月我院诊治的192例NAFLD和106例NAFLD合并T2DM患者【单纯性脂肪肝(SFL)76例,非酒精性脂肪性肝炎(NASH)21例,肝硬化9例】,采用ELISA法检测血清HCY、FGF21和NF-κB水平,使用FibroTouch行肝脏硬度检测(LSM)发现肝纤维化S0～S1期75例,S2～S4期31例。结果 NAFLD合并T2DM组血清低密度脂蛋白(LDL-C)、空腹血糖(FPG)和糖化血红蛋白(HbA1c)水平分别为(3.9±0.7)mmol/L、(8.6±1.3)mmol/L和(8.1±1.7)%,均显著高于NAFLD组【分别为(3.1±0.6)mmol/L、(5.2±1.1)mmol/L和(5.7±1.0)%,P<0.05】,而血清高密度脂蛋白胆固醇(HDL-C)水平为(1.0±0.2)mmol/L,显著低于NAFLD组【(1.4±0.2)mmol/L,P<0.05】;NAFLD合并T2DM组血清HCY、FGF21和NF-κB水平分别为(17.8±2.3)μmol/L、(315.2±32.5)pg/ml和(4.1±0.8)pg/mL,显著高于NAFLD组【分别为(14.1±1.9)μmol/L、(278.9±30.7)pg/ml和(2.8±0.5)pg/mL,P<0.05】;肝硬化患者血清HCY和NF-κB水平分别为(20.3±2.1)μmol/L和(5.0±1.0)pg/mL,显著高于NASH组【分别为(18.9±1.9)μmol/L和(4.5±0.7)pg/mL,P<0.05】或SFL组【分别为(16.2±1.6)μmol/L和(3.9±0.6)pg/mL,P<0.05】,而血清FGF21水平为(284.7±30.5)pg/ml,显著低于NASH组【(337.8±25.1)pg/ml,P<0.05】或SFL组【(312.5±28.3)pg/ml,P<0.05】;肝纤维化S2～S4期血清HCY和NF-κB水平分别为(20.9±1.8)μmol/L和(5.1±1.1)pg/mL,显著高于S0～S1期【(17.2±2.1)μmol/L和(3.9±0.8)pg/mL,P<0.05】,而血清FGF21水平为(291.1±26.7) pg/ml,显著低于S0～S1期【(319.8±28.3)pg/ml,P<0.05】。结论 NAFLD合并T2DM患者血清HCY、FGF21和NF-κB水平显著高于NAFLD患者,且这些指标与NAFLD临床分型和肝纤维化程度有关。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 同型半胱氨酸, 成纤维细胞生长因子21, 核因子-κB

Abstract: Objective The aim of this study was to explore the implication of serum homocystein (HCY), fibroblast growth factor-21 (FGF21) and nuclear factor-κB (NF-κB) levels in patients with non-alcoholic fatty liver diseases (NAFLD) and type 2 diabetes mellitus (T2DM). Methods A total of 192 patients with NAFLD and 106 patients with NAFLD and T2DM were enrolled in our hospital between May 2020 and March 2022. Serum HCY, FGF-21 and NF-κB levels were detected by ELISA. The fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) were detected by glucose oxidase and high performance liquid chromatography, respectivley. The patients with NAFLD and T2DM were divided into simple fatty liver (SFL) in 76 cases, nonalcoholic steatohepatitis (NASH) in 21 cases and cirrhosis in 9 cases. All patients underwent liver stiffness measurement (LSM) by FibroTouch, and the liver fibrosis stage S0-S1 was found in 75 cases and stage S2-S4 in 31 cases. Results Serum LDL-C, FPG and HbA1c levels in patients with NAFLD and T2DM were (3.9±0.7)mmol/L, (8.6±1.3)mmol/L and (8.1±1.7)%, all significantly higher than [(3.1±0.6) mmol/L, (5.2±1.1)mmol/L and (5.7±1.0)%, P<0.05], while serum HDL-C level was (1.0±0.2)mmol/L, significantly lower than [(1.4±0.2)mmol/L, P<0.05] in patients with NAFLD; serum HCY, FGF21 and NF-κB levels in patients with NAFLD and T2DM were (17.8±2.3)μmol/L, (315.2±32.5) pg/ml and (4.1±0.8)pg/mL, significantly higher than [(14.1±1.9)μmol/L, (278.9±30.7)pg/ml and (2.8±0.5)pg/mL, respectively, P<0.05] in patients with NAFLD; serum HCY and NF-κB levels in patients with cirrhosis were (20.3±2.1)μmol/L and (5.0±1.0)pg/mL, both significantly higher than [(18.9±1.9)μmol/L and (4.5±0.7)pg/mL, P<0.05] in patients with NASH or [(16.2±1.6)μmol/L and (3.9±0.6)pg/mL, P<0.05] in patients with SFL, while serum FGF21 level was (284.7±30.5)pg/ml, significantly lower than [(337.8±25.1)pg/ml, P<0.05] in patients with NASH or [(312.5±28.3)pg/ml, P<0.05] in patients with SFL; serum HCY and NF-κB levels in patients with liver fibrosis staging S2-S4 were (20.9±1.8)μmol/L and (5.1±1.1)pg/mL, both significantly higher than [(17.2±2.1)μmol/L and (3.9±0.8)pg/mL, P<0.05] in patients with staging S0-S1, while serum FGF21 level was (291.1±26.7) pg/ml, significantly lower than [(319.8±28.3)pg/ml, P<0.05] in patients with staging S0-S1. Conclusion Serum HCY, FGF21 and NF-κB levels significantly increase in patients with NAFLD and T2DM, which might be related to clinical catalogues of NAFLD and the severity of liver fibrosis.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Homocystein, Fibroblast growth factor-21, Nuclear factor-κB

李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.

Li Xiaomeng, Wu Shaoyu, Wang Yuanyuan. Implication of serum homocystein, fibroblast growth factor-21 and nuclear factor-κB levels in patients with non-alcoholic fatty liver diseases and T2DM[J]. Journal of Practical Hepatology, 2023, 26(2): 202-205.

参考文献

[1] 中华医学会内分泌学分会, 中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识. 中华内分泌代谢杂志, 2021, 37(7): 589-598.
[2] 温林. 非酒精性脂肪性肝病合并2型糖尿病患者血尿酸水平变化及其临床意义. 实用肝脏病杂志, 2021, 24(1): 55-58.
[3] 陈丽丽, 符茂雄, 刘正金, 等. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨. 实用肝脏病杂志, 2020, 23(5): 658-661.
[4] Barb D, Bril F, Kalavalapalli S, et al. Plasmafibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with Oobesity and type 2 diabetes. J Clin Endocrinol Metab, 2019, 104(8): 3327-3336.
[5] Ritchie M, Hanouneh IA, Noureddin M, et al. Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? Expert Opin Investig Drugs, 2020, 29(2): 197-204.
[6] 孙明珠, 李秀丽, 许楠, 等. 老年2型糖尿病合并非酒精性脂肪肝患者血清蛋白激酶Cε活性和胰岛素抵抗的关系研究. 中华老年医学杂志, 2020, 39(3): 287-290.
[7] 信丰智, 范建高. 欧洲非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志, 2016, 19(4): ⅤⅡ-ⅤⅢ.
[8] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 2型糖尿病基层诊疗指南(实践版·2019). 中华全科医师杂志, 2019, 18(9): 810-818.
[9] 葛海燕, 匡霞, 周瑞君. 非酒精性脂肪性肝病合并2型糖尿病患者血清miR-17, miR-20a和miR-20b变化及其临床意义. 实用肝脏病杂志, 2021, 24(5): 97-700.
[10] Xu K, Zhao X, Fu X, et al. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study. Biomed Pharmacother, 2019, 117(9): e109158.
[11] Wu L, Qian L, Zhang L, et al. Fibroblastgrowth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. J Am Heart Assoc, 2020, 9(11): e015226.
[12] Rader DJ, Maratos-Flier E, Nguyen A, et al. LLF580, an FGF21analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab, 2022, 107(1): e57-e70.
[13] Dushay J, Lai M. Is trimming the fat enough? Fibroblast growth factor 21 as an emerging treatment for nonalcoholic fatty liver disease. Hepatology, 2019, 70(5): 1860-1862.
[14] Bian H, Zhu X, Xia M, et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis andadvanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract, 2020, 26(4): 444-453.
[15] Byun S, Seok S, Kim YC, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. NatCommun, 2020, 11(1): 807-810.
[16] Kim HY, Kwon WY, Park JB, et al. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease. FASEB J, 2020, 34(9): 12354-12366.
[17] Zarei M, Pizarro-Delgado J, Barroso E, et al. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol Sci, 2020, 41(3): 199-208.
[18] Sharma D, Garg S, Mehndiratta M, et al. Association of apolipoprotein A-V with mRNA expression of IL-6 and NF-κB genes in type 2 diabetes with hypertriglyceridemia: a possible link with inflammation. Int J Diabetes Dev Ctries, 2019, 39(Suppl 1): 1-9.
[19] Liang H, Wang H, Luo L, et al. Toll-like receptor 4 promotes high glucose-induced catabolic and inflammatory responses in chondrocytes in an NF-κB-dependent manner. Life Sci, 2019, 228(6): 258-265.
[20] Zhang Y, Li J, Liu H. Correlation between the thyroid hormone levels and nonalcoholic fatty liver disease in type 2 diabetic patients with normal thyroid function. BMC Endocr Disord, 2022, 22(1): 144-149.
[21] Ji J, Liu Y, Liu H, et al. Relationship betweenprocalcitonin, homocysteine and severity of coronary artery disease in type 2 diabetic patients. Int J Gerontol, 2019, 13(3): 226-230.

非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*

Implication of serum homocystein, fibroblast growth factor-21 and nuclear factor-κB levels in patients with non-alcoholic fatty liver diseases and T2DM

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[2]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[3]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[4]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[5]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[6]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[7]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[8]	徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.
[9]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[10]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[11]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[12]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.
[13]	孙凌, 杭玮, 邓国忠. 二甲双胍联合吡格列酮治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 804-807.
[14]	王晓华, 曾雅琳, 郭萃蓉. 非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查^*[J]. 实用肝脏病杂志, 2022, 25(6): 812-815.
[15]	樊叶, 张喜梅, 张岩. 非酒精性脂肪性肝病患者血清胱抑素C、脂蛋白α和nesfatin-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 816-819.